Antifungal Drugs Market

Executive Summary

Antifungal Drugs Market was valued at US $13.63 billion in 2021 and is projected to grow at 4.02% CAGR over the forecast period to reach US $17.26 billion by 2027. Antifungal Drugs Market represented US $1.03 billion opportunity over 2019-2021 and estimated to create US $3.63 billion opportunity in 2027 over 2021.

Antifungal Drugs from Consainsights analyses the Antifungal Drugs Market in the Life Sciences industry over the forecast period to 2027.

Antifungal Drugs research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Antifungal Drugs segmentation includes Infection Type, Drug Type, Therapeutic Indications, Dosage Forms and Geography.

Based on the Infection Type, the Antifungal Drugs analysis covers SUPERFICIAL ANTIFUNGAL INFECTION, SYSTEMIC ANTIFUNGAL INFECTION.

In Infection Type segment, SUPERFICIAL ANTIFUNGAL INFECTION segment has highest cagr growth of 3.56%.

Based on the Drug Type, the Antifungal Drugs analysis covers ECHINOCANDINS, AZOLES, POLYENES, ALLYLAMINES, OTHERS.

In Drug Type segment, ECHINOCANDINS segment has highest cagr growth of 3.56%.

Based on the Therapeutic Indications, the Antifungal Drugs analysis covers ASPERGILLOSIS, DERMATOPHYTOSIS, CANDIDIASIS, OTHERS.

In Therapeutic Indications segment, ASPERGILLOSIS segment has highest cagr growth of 3.56%.

Based on the Dosage Forms, the Antifungal Drugs analysis covers POWDER, OINTMENTS, DRUGS, OTHERS.

In Dosage Forms segment, POWDER segment has highest cagr growth of 3.56%.

Based on the region, the Antifungal Drugs analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include PFIZER INC., SANOFI S.A, GILEAD SCIENCES INC., MERCK & CO., INC., NOVARTIS INTERNATIONAL AG, ABBOTT LABORATORIES, BAYER AG, SCYNEXIS INC., ENZON PHARMACEUTICALS INC., GLAXOSMITHKLINE PLC and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Infection Type

Introduction

In 2021, SUPERFICIAL ANTIFUNGAL INFECTION segment has the highest revenue of US $7.61 billion and is expected to grow at CAGR of 3.56% by 2027 SUPERFICIAL ANTIFUNGAL INFECTION segment has highest cagr growth of 3.56%.

SUPERFICIAL ANTIFUNGAL INFECTION

SUPERFICIAL ANTIFUNGAL INFECTION segment was valued at US $7.03 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $9.63 billion by 2027. SUPERFICIAL ANTIFUNGAL INFECTION segment represented US $0.58 billion opportunity over 2019-2021 and estimated to create US $2.03 billion opportunity in 2027 over 2021.

SYSTEMIC ANTIFUNGAL INFECTION

SYSTEMIC ANTIFUNGAL INFECTION segment was valued at US $5.56 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $7.62 billion by 2027. SYSTEMIC ANTIFUNGAL INFECTION segment represented US $0.46 billion opportunity over 2019-2021 and estimated to create US $1.60 billion opportunity in 2027 over 2021.

Drug Type

Introduction

In 2021, ECHINOCANDINS segment has the highest revenue of US $5.89 billion and is expected to grow at CAGR of 3.56% by 2027 ECHINOCANDINS segment has highest cagr growth of 3.56%.

ECHINOCANDINS

ECHINOCANDINS segment was valued at US $5.44 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $7.46 billion by 2027. ECHINOCANDINS segment represented US $0.45 billion opportunity over 2019-2021 and estimated to create US $1.57 billion opportunity in 2027 over 2021.

AZOLES

AZOLES segment was valued at US $3.57 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $4.89 billion by 2027. AZOLES segment represented US $0.29 billion opportunity over 2019-2021 and estimated to create US $1.03 billion opportunity in 2027 over 2021.

POLYENES

POLYENES segment was valued at US $1.85 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $2.53 billion by 2027. POLYENES segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.53 billion opportunity in 2027 over 2021.

ALLYLAMINES

ALLYLAMINES segment was valued at US $1.38 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $1.88 billion by 2027. ALLYLAMINES segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.40 billion opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $0.36 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $0.49 billion by 2027. OTHERS segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.10 billion opportunity in 2027 over 2021.

Therapeutic Indications

Introduction

In 2021, ASPERGILLOSIS segment has the highest revenue of US $5.87 billion and is expected to grow at CAGR of 3.56% by 2027 ASPERGILLOSIS segment has highest cagr growth of 3.56%.

ASPERGILLOSIS

ASPERGILLOSIS segment was valued at US $5.43 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $7.44 billion by 2027. ASPERGILLOSIS segment represented US $0.44 billion opportunity over 2019-2021 and estimated to create US $1.57 billion opportunity in 2027 over 2021.

DERMATOPHYTOSIS

DERMATOPHYTOSIS segment was valued at US $3.92 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $5.37 billion by 2027. DERMATOPHYTOSIS segment represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $1.13 billion opportunity in 2027 over 2021.

CANDIDIASIS

CANDIDIASIS segment was valued at US $2.85 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $3.91 billion by 2027. CANDIDIASIS segment represented US $0.23 billion opportunity over 2019-2021 and estimated to create US $0.82 billion opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $0.40 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $0.55 billion by 2027. OTHERS segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.12 billion opportunity in 2027 over 2021.

Dosage Forms

Introduction

In 2021, POWDER segment has the highest revenue of US $6.58 billion and is expected to grow at CAGR of 3.56% by 2027 POWDER segment has highest cagr growth of 3.56%.

POWDER

POWDER segment was valued at US $6.08 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $8.33 billion by 2027. POWDER segment represented US $0.50 billion opportunity over 2019-2021 and estimated to create US $1.75 billion opportunity in 2027 over 2021.

OINTMENTS

OINTMENTS segment was valued at US $4.50 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $6.17 billion by 2027. OINTMENTS segment represented US $0.37 billion opportunity over 2019-2021 and estimated to create US $1.30 billion opportunity in 2027 over 2021.

DRUGS

DRUGS segment was valued at US $1.41 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $1.93 billion by 2027. DRUGS segment represented US $0.12 billion opportunity over 2019-2021 and estimated to create US $0.41 billion opportunity in 2027 over 2021.

OTHERS

OTHERS segment was valued at US $0.61 billion in 2019 and is projected to grow at 3.56% CAGR over the forecast period to reach US $0.84 billion by 2027. OTHERS segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.18 billion opportunity in 2027 over 2021.